Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Association between plasma bilirubin and mortality

L. Vitek, JA. Hubacek, A. Pajak, A. Doryńska, M. Kozela, L. Eremiasova, V. Danzig, D. Stefler, M. Bobak,

. 2019 ; 18 (2) : 379-385. [pub] 20190418

Jazyk angličtina Země Mexiko

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022926

INTRODUCTION AND AIM: It has been proposed that plasma concentration of bilirubin, an endogenous antioxidant, is protective against diseases mediated by increased oxidative stress, including cardiovascular diseases (CVD) and cancer. To examine this hypothesis, we investigated the relationship between plasma bilirubin concentrations and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variations (associated with increased bilirubin concentrations) with total/CVD and cancer mortality. MATERIALS AND METHODS: A nested case-control study was conducted within the Polish arm of the HAPIEE cohort. At baseline in 2002-2005, participants were examined in detail. Mortality follow-up (median (IQR) between blood draw and death was 3.7 (2.1-5.1) years) was performed by linkage with regional and national death registers. Plasma biomarkers were analysed in all subjects who died from any cause (cases, n=447) and in a random subsample of survivors (controls, n=1423). RESULTS: There was a strong negative association between plasma bilirubin levels and total and cancer mortality, expressed more profoundly in men. The adjusted OR of deaths from all causes and cancer, comparing the highest vs. lowest plasma bilirubin categories were 0.61 (95% CI: 0.42-0.87) and 0.39 (0.24-0.65), respectively. There was no association of bilirubin with CVD mortality. The UGT1A1*28 allele, a genetic marker of raised bilirubin, was also negatively associated with total/cancer mortality, although the associations were not statistically significant. DISCUSSION: Both the observational and genetic associations support the negative relationship between bilirubin and total mortality; this association appears to be driven by cancer mortality, while that with CVD mortality is not evident.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022926
003      
CZ-PrNML
005      
20201214125000.0
007      
ta
008      
201125s2019 mx f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.aohep.2019.02.001 $2 doi
035    __
$a (PubMed)31054979
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a mx
100    1_
$a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: vitek@cesnet.cz.
245    10
$a Association between plasma bilirubin and mortality / $c L. Vitek, JA. Hubacek, A. Pajak, A. Doryńska, M. Kozela, L. Eremiasova, V. Danzig, D. Stefler, M. Bobak,
520    9_
$a INTRODUCTION AND AIM: It has been proposed that plasma concentration of bilirubin, an endogenous antioxidant, is protective against diseases mediated by increased oxidative stress, including cardiovascular diseases (CVD) and cancer. To examine this hypothesis, we investigated the relationship between plasma bilirubin concentrations and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variations (associated with increased bilirubin concentrations) with total/CVD and cancer mortality. MATERIALS AND METHODS: A nested case-control study was conducted within the Polish arm of the HAPIEE cohort. At baseline in 2002-2005, participants were examined in detail. Mortality follow-up (median (IQR) between blood draw and death was 3.7 (2.1-5.1) years) was performed by linkage with regional and national death registers. Plasma biomarkers were analysed in all subjects who died from any cause (cases, n=447) and in a random subsample of survivors (controls, n=1423). RESULTS: There was a strong negative association between plasma bilirubin levels and total and cancer mortality, expressed more profoundly in men. The adjusted OR of deaths from all causes and cancer, comparing the highest vs. lowest plasma bilirubin categories were 0.61 (95% CI: 0.42-0.87) and 0.39 (0.24-0.65), respectively. There was no association of bilirubin with CVD mortality. The UGT1A1*28 allele, a genetic marker of raised bilirubin, was also negatively associated with total/cancer mortality, although the associations were not statistically significant. DISCUSSION: Both the observational and genetic associations support the negative relationship between bilirubin and total mortality; this association appears to be driven by cancer mortality, while that with CVD mortality is not evident.
650    _2
$a senioři $7 D000368
650    _2
$a bilirubin $x krev $7 D001663
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a kardiovaskulární nemoci $x krev $x diagnóza $x genetika $x mortalita $7 D002318
650    _2
$a příčina smrti $7 D002423
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glukuronosyltransferasa $x genetika $7 D014453
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mendelovská randomizace $7 D057182
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory $x krev $x diagnóza $x genetika $x mortalita $7 D009369
650    _2
$a polymorfismus genetický $7 D011110
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a sexuální faktory $7 D012737
650    _2
$a časové faktory $7 D013997
651    _2
$a Polsko $x epidemiologie $7 D011044
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hubacek, Jaroslav A $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Pajak, Andrzej $u Chair of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland.
700    1_
$a Doryńska, Agnieszka $u Chair of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland.
700    1_
$a Kozela, Magdalena $u Chair of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland.
700    1_
$a Eremiasova, Lenka $u 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Danzig, Vilem $u 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Stefler, Denes $u Department of Epidemiology and Public Health, University College of London, UK.
700    1_
$a Bobak, Martin $u Department of Epidemiology and Public Health, University College of London, UK.
773    0_
$w MED00172549 $t Annals of hepatology $x 1665-2681 $g Roč. 18, č. 2 (2019), s. 379-385
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31054979 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214125000 $b ABA008
999    __
$a ok $b bmc $g 1595245 $s 1113602
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 18 $c 2 $d 379-385 $e 20190418 $i 1665-2681 $m Annals of hepatology $n Ann Hepatol $x MED00172549
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace